PLK1 inhibition enhances temozolomide efficacy in IDH1 mutant gliomas

Despite multimodal therapy with radiation and the DNA alkylating agent temozolomide (TMZ), malignant gliomas remain incurable. Up to 90% of grades II-III gliomas contain a single mutant isocitrate dehydrogenase 1 (IDH1) allele. IDH1 mutant-mediated transformation is associated with TMZ resistance; h...

Descripción completa

Detalles Bibliográficos
Autores principales: Koncar, Robert F., Chu, Zhengtao, Romick-Rosendale, Lindsey E., Wells, Susanne I., Chan, Timothy A., Qi, Xiaoyang, Bahassi, El Mustapha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362526/
https://www.ncbi.nlm.nih.gov/pubmed/28178660
http://dx.doi.org/10.18632/oncotarget.15015

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5362526/
https://www.ncbi.nlm.nih.gov/pubmed/28178660
http://dx.doi.org/10.18632/oncotarget.15015

Ejemplares similares